there's an app for that

Houston-area health services company launches COVID-19 pre-screening app

A Houston-area company has created an easy-to-use health-check app for employees returning to work. Pexels

A Woodlands-based health services company recently announced a new app that can serve as a self-service pre-screening tool for COVID-19 to be used by employees to return to their workplace.

Axiom Medical created the CheckIn2Work app to make the transition into the workplace after the coronavirus crisis safer and easier, making it simple for businesses and offices to reopen after stay-at-home orders shut down workplaces during the height of the pandemic.

"Given the current challenges we have all experienced with COVID-19, we recognize the workplace will be forever changed," says Axiom Medical President and CEO Mark Robinson. "Our CheckIn2Work app simply adds another layer to protecting the health of team members, customers, and vendors from the risk of infectious disease in the workplace."

The app includes features such as a 24/7 self-service illness screening with the latest screening criteria approved by Chief Medical Officer Scott Cherry. The app also includes immediate access to U.S.-based Clearance Center for exposure/illness alerts, real-time reporting, and ongoing best practices to reduce the spread of the virus in the work environment.

When an app user is flagged as exposed to the virus, Axiom Medical's Rapid Response Contagious Respiratory Illness Assessment Clearance Center professionals can conduct secondary screening procedures via a phone call to confirm cases and eliminate false positives.

The app has 50,000 users already from Axiom's new and existing clients who have signed on to the platform. Some of their partners include BJ Services, Tyson Foods, ISS Facility Services, and Fort Bend Kia, Robinson says it creates safe and healthy facilities for both employees and customers.

"It enables our clients to be appropriately responsive to trying to screen out the infection in their workplace," says Robinson, "It also gives employees confidence that returning to work and exposing themselves to their coworkers is safe while providing customers who have contact with the employees with the confidence who they will be interacting with has been screened and cleared."

For the health services company, keeping employees safe has been the heart of their mission since it was founded more than two decades ago. Axiom Medical markets itself as an employer's outsourced "in house" medical department, managing a complete array of occupational health services such as scheduling exams, verifying results for accuracy, and maintaining records.

"Our focus is on the health of the worker in the workplace," says Robinson. "Both our traditional services and our new service all focus on keeping people as healthy as possible, returning them to work as quickly as possible after an injury or illness keeps them out of the workplace, and making sure they are tested for a variety of risks."

CheckIn2Work is now available on iOS and Android mobile devices including a web portal where employees can check in before work every day to check for symptoms of COVID-19. The app is adaptable with language settings in English and Spanish and allows for customizable questions to fit an organization's needs.

"I hope we can continue to take this seriously and take good precautions," says Robinson. "This is a really horrible disease, it isn't just about the people who die as a result, it's also about those who are permanently disabled because of it. Those weeks in a hospital are mirrored by more weeks in recovery before they can even think about working again."

Trending News

Building Houston

 
 

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Trending News